SCHEMBL3093901

SCHEMBL3093901

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2ccccc2)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 2/20 0.46
LMNA P02545 1/20 0.46
GPR27 Q9NS67 1/20 0.45
LARS1 Q9P2J5 1/20 0.45
KAT6A Q92794 1/20 0.44
F2 P00734 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
PLG P00747 1/20 0.42
PPARA Q07869 1/20 0.42
OPRD1 P41143 1/20 0.42
OPRK1 P41145 1/20 0.42
PRMT1 Q99873 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102970 1.00 MMP9 (0.46) MMP9LMNAGPR27LARS1KAT6A
SCHEMBL3090792 0.94 NPC1 (0.51) MMP9LMNAGPR27LARS1KAT6A
SCHEMBL3092998 0.94 NPC1 (0.51) MMP9LMNAGPR27LARS1KAT6A
SCHEMBL3090637 0.93 RAB9A (0.48) LMNAGPR27LARS1MEN1KMT2A
SCHEMBL3093732 0.93 LARS1 (0.44) MMP9LMNAGPR27LARS1F2
SCHEMBL3090974 0.93 MEN1 (0.50) GPR27LARS1KAT6AF2PPARA
SCHEMBL3100522 0.93 MMP9 (0.45) MMP9LMNAGPR27LARS1KAT6A
Hydrochloric Acid SCHEMBL3089133 0.92 SMN1; SMN2 (0.45) MMP9LMNAGPR27LARS1F2
SCHEMBL3092720 0.92 MEN1 (0.53) LMNAGPR27LARS1KAT6AF2
SCHEMBL3100199 0.92 NPC1 (0.53) MMP9LMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MMP9 1227/4885LMNA 3803/4885GPR27 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.